Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: Department of Health (Therapeutic Goods Administration)
risperidone, Quantity: 0.5 mg
Dr Reddys Laboratories Australia Pty Ltd
Risperidone
Tablet, film coated
Excipient Ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; sodium lauryl sulfate; purified talc; titanium dioxide; hypromellose; iron oxide red; macrogol 400
Oral
20, 60 tablet
(S4) Prescription Only Medicine
Treatment of schizophrenia and related psychoses. Short-term treatment of acute mania associated with bipolar I disorder. Treatment (up to 12 weeks) of psychotic symptoms, or persistent agitations or aggression unresponsive to non-pharmacological approaches, in patients with moderate to severe dementia of the Alzheimer type. Treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials for maintenance data). Treatment of behavioural disorders associated with autism in children and adolescents (see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials).
Visual Identification: Brown, capsule shaped, biconvex film coated tablets embossed with '0.5' on one side and 'RSP' on the other side with a scoreline separating 'R' and 'SP'; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2010-05-12
Page 1 of 34 RESPAZ PRODUCT INFORMATION NAME OF THE MEDICINE Active: Risperidone DESCRIPTION Chemical Name: 3-[2-[4-(6-fluoro –1,2-benzisoxazol –3-yl) –1-piperidinyl] ethyl] –6,7,8,9- tetrahydro –2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one. Molecular formula: C 23 H 27 FN 4 O 2 Molecular Weight: 410.49 CAS: 106266-06-2 Excipients: Lactose, pregelatinised maize starch, microcrystalline cellulose, sodium lauryl sulfate, colloidal anhydrous silica, purified talc, magnesium stearate. In addition, the 0.5 mg tablet contains Opadry complete film coating system 03B56980j Brown; the 1 mg tablet contains Opadry complete film coating system OY-58900 White; the 2 mg tablet contains Opadry complete film coating system 03B53509 Orange; the 3 mg tablet contains Opadry complete film coating system 03B52209 Yellow; and the 4 mg tablet contains Opadry complete film coating system 03B51293 Green. PHARMACOLOGY Risperidone is a novel antipsychotic belonging to a new class of antipsychotic agents, the benzisoxazole derivatives. PHARMACODYNAMICS Risperidone is a selective monoaminergic antagonist with a high affinity for serotoninergic 5HT2- receptors and dopaminergic D 2 -receptors. Risperidone binds also to alpha 1 -adrenergic receptors and, with lower affinity, to H 1 -histaminergic and alpha 2 -adrenergic receptors. Risperidone has no affinity for cholinergic receptors. The antipsychotic activity of risperidone is considered to be attributable to both risperidone and its active metabolite 9-hydroxy risperidone. _Product Information _ _Respaz (risperidone tablets) _ _Dr Reddy’s Laboratories (Australia) Pty Ltd _ _Version 2 09May11 _ Page 2 of 34 Central dopamine D 2 -receptor antagonism is considered to be the mechanism of action by which conventional neuroleptics improve the positive symptoms of schizophrenia, but also induce extrapyramidal symptoms and release of prolactin. Although risperidone antagonises dopamine D 2 -receptors and causes release of prolactin, it is less potent than classical neuroleptics for depress Đọc toàn bộ tài liệu